Table 3.
Hazard ratios (HRs) and 95% confidence intervals (CIs) for distant metastasis-free survival (DMFS).
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| HRs (95% CIs) | p value | HRs (95% CIs) | p value | |
| Age (continuous) | 1.024 (0.968–1.082) | 0.408 | N/A | |
| BMI | 1.005 (0.861–1.173) | 0.949 | N/A | |
| ER | 0.119 | N/A | ||
| Negative | 1 | |||
| Positive | 0.569 (0.200–1.624) | |||
| PR | 0.098 | N/A | ||
| Negative | 1 | |||
| Positive | 0.397 (0.133–1.184) | |||
| HER2 | 0.836 | N/A | ||
| Negative | 1 | |||
| Positive | 1.131 (0.355–3.605) | |||
| HG | 0.994 | N/A | ||
| I, II | 1 | |||
| III | 0.998 (0.562–1.772) | |||
| Tumor size | 0.119 | N/A | ||
| ≤ 2 cm | 1 | |||
| > 2 cm | 2.320 (0.804–6.688) | |||
| Lymph node metastasis | 0.052 | N/A | ||
| Negative | 1 | |||
| Positive | 2.859 (0.992–8.241) | |||
| AJCC stage | 0.015 | 0.019 | ||
| I | 1 | 1 | ||
| II | 6.024 (1.301–27.886) | 5.810 (1.255–26.900) | ||
| III | 7.125 (1.190–42.650) | 6.631 (1.106–39.734) | ||
| Lymphovascular invasion | 0.693 | N/A | ||
| Negative | 1 | |||
| Positive | 1.301 (0.352–4.815) | |||
| SUVmean-VAT | 0.031 | 0.039 | ||
| Low | 1 | 1 | ||
| High | 4.066 (1.134–14.580) | 3.846 (1.072–13.795) | ||
| Chemotherapy | 0.392 | N/A | ||
| Not done | 1 | |||
| Done | 0.630 (0.218–1.815) | |||
| Radiotherapy | 0.915 | N/A | ||
| Not done | 1 | |||
| Done | 0.944 (0.327–2.723) | |||
| Endocrine therapy | 0.082 | N/A | ||
| Not done | 1 | |||
| Done | 0.390 (0.135–1.125) | |||
BMI Body mass index; ER Estrogen receptor; PR Progesterone receptor; HER2 Human epidermal growth factor receptor 2; HG Histologic grade; VAT Visceral adipose tissue; N/A Not assessed.